

An unexpected aminocyclopropane reductive rearrangement

Joey L. Methot^{*}, Theresa A. Dunstan[†], Dawn M. Mampreian, Bruce Adams,
Michael D. Altman

Department of Drug Design and Optimization, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, United States

Received 27 November 2007; revised 10 December 2007; accepted 11 December 2007

Available online 8 January 2008

Abstract

A reductive rearrangement of aminocyclopropanes is described for the synthesis of *cis*- or *trans*-fused bicyclic 1,2-diaminocyclobutanes. Ionization of a cyclic aminal using $\text{BF}_3 \cdot \text{OEt}_2$ induces rearrangement to a cyclobutyl iminium ion, which is subsequently reduced by Et_3SiH . Substitution with allyltrimethylsilane allows carbon incorporation, giving a quaternary center. Silyloxy-substituted cyclopropanes rearrange rapidly to cyclobutanones which react with NaBH_4 to provide 1,2-aminohydroxycyclobutanes. These aminals were generated by the reduction of a Boc-imide with DIBAL-H or LiBH_4 .

© 2007 Elsevier Ltd. All rights reserved.

Keywords: Aminocyclopropane; Cyclobutane; Piperazine; Imidazolidinone; Rearrangement

Piperazines are versatile heterocycles in medicinal chemistry, for example, as solubilizing or hydrophobic groups, or as scaffolds that can orient substituents in a rigid fashion.¹ A recent search of the MDL drug report database listed over 70 marketed drugs containing a piperazine,² with examples including the active ingredients in *Viagra*TM, *Januvia*TM, and *Crixivan*TM. However, piperazines are also prone to metabolism through imine formation, a process that can occasionally be prevented with substitution about the ring.³ Imidazolidinones are somewhat less popular, *Tanatril*TM being recently launched for the treatment of hypertension. As part of a medicinal chemistry program we became interested in cyclopropyl piperazine **5**.

We planned to prepare piperazine **5** by the reduction of diketopiperazine **4**, a well-established approach for the synthesis of substituted piperazines.⁴ Commercially available *N*-Cbz cyclopropyl amino acid **1** was coupled to glycine methyl ester using HOBt and EDC giving dipeptide **2** in 68% yield. Hydrogenolysis followed by heating oily **3** to

150 °C neat for 10 min cleanly provided **4** as a white solid. However, numerous attempts at reduction of the bislactam rendered unreacted substrate and/or complex mixtures containing **5**.



Concerned about the sensitivity of the aminocyclopropane moiety to the typically harsh reaction conditions required for amide reduction, we considered a milder two-step reduction process via Boc diimide **6**; prepared from **4** by treatment with Boc_2O and DMAP at ambient temperature. A solution of **6** in THF was treated at –78 °C with 4 equiv of DIBAL-H for 1 h giving diol **7** in 84% yield as a 3:1 mixture of diastereomers after an aqueous work-up. Next, a solution **7** in DCM was treated at –78 °C with 4 equiv each of $\text{BF}_3 \cdot \text{OEt}_2$ and Et_3SiH for 2 h.⁵ To our surprise, the white solid product isolated was not the planned cyclopropyl piperazine derivative but instead the rearranged cyclobutyl piperazine **8**.⁶

Bicycle **8** is a new piperazine which rigidifies the conformation of the piperazine scaffold and may also hinder metabolism. The symmetry of **8** however complicates stereochemical analysis, and so derivative **9**⁷ was prepared to desymmetrize the piperazine, which was then subjected to NOESY experiments. The lack of any observed NOE

^{*} Corresponding author. Tel.: +1 617 992 2054.

E-mail address: joey_methot@merck.com (J. L. Methot).

[†] Northeastern University co-op program participant.




at either methine when the other is inverted, coupled with transannular effects around cyclobutane and with the adjacent pyridine ring clearly indicates that the bicycle is *trans*-fused. The coupling constant of ~ 7 Hz between methine protons is consistent with this assignment.

Reduction of diol **7** was nearly as effective using $\text{EtMe}_2\text{-SiH}$ (50% yield) but not with CyMe_2SiH (29% yield), while $(\text{MeO})_3\text{SiH}$ gave an uncharacterized mixture of products.


Efforts to combine the separate reduction steps in a single pot from **6** failed to yield product **8** in good yield.⁸

It is reasonable that the more accessible alcohol of **7** is reduced first, giving intermediate **10**. A second ionization would then lead to iminium ion **11** which would rearrange to a more stable iminium ion **12**, followed by triethylsilane reduction that would follow an axial trajectory. We estimate that iminium ion **12** is 2–4 kcal/mol lower in energy

than iminium ion **11**, based on DFT and HF calculations at the B3LYP/6-31G* and RHF/6-31++G** levels of theory, respectively.⁹ This is consistent with the ring strain energy of a cyclopropane being ~3 kcal/mol greater than that of a cyclobutane.¹⁰




While the rearrangement to form novel bicyclic piperazine **8** is of interest, there remained a need to access cyclopropyl piperazine. Lactam cyclopropanation using a modified Kulinkovich reaction with MeTi(OiPr)₃/EtMgBr is a well-established method for the preparation of cyclopropyl amines.¹¹ Lactam **13** derived from the commercially available phenylpiperazinone undergoes clean cyclopropanation to give **14**.




Over the course of exploring this sequence with various imides, we turned to imidazolidinediones such as **17** formed from cyclopropyl aminoamide **15** by treatment with Boc₂O and DMAP at elevated temperature. In contrast, methylamine **16** cyclized rapidly to **18** at ambient temperature.¹² Imidazolidinediones **17** and **18** both react cleanly with DIBAL-H at –78 °C to give hydroxyimidazolidinones **19** and **20** in 61% and 69% yield, respectively. Then as expected treatment with 2 equiv each of BF₃·OEt₂ and Et₃SiH at –78 °C gave rearrangement to the bicyclic imidazolidinones **21** and **22** in 57% and 73% yields, respectively. Alternatively, trapping the intermediate iminium ions with 2 equiv of allyl trimethylsilane giving **23** and **24** in 43–51% yield is promising for more general carbon incorporation.¹³ In contrast to piperazine **8**, NOESY experiments with **22** and **24** indicate a *cis*-fused bicycle.

Oxazolidinedione **26** was prepared in an analogous fashion from amide **25** and reduced with LiBH₄ at ambient temperature to give the intermediate hydroxyoxazolidinone. Then in stark contrast to the imidazolidinone series, exposure to 3 equiv each of BF₃·OEt₂ and Et₃SiH at –78 °C gave clean reduction to **27** in 72% overall yield; this time with the cyclopropane intact. It is likely that the nitrogen in the imidazolidinone series is a better donor than the oxygen in the oxazolidinone.

An alternative route to bicyclic oxazolidinones is from the acyclic silyloxy cyclopropane **28**. Treatment with DIBAL-H at –78 °C gave the acyclic amina **29** following an aqueous work-up.¹⁴ When a solution of crude amina **29** in DCM was treated at –78 °C with BF₃·OEt₂, a rearrangement and concomitant loss of the silyl protective group gave cyclobutanone **30** in 59% overall two-step yield.¹⁵ The addition of triethylsilane had no effect in this transformation. Finally, reduction with NaBH₄ provides






access to the bicyclic oxazolidinone **31**. This represents a novel route to 2-aminocyclobutanones which are useful substrates for the preparation of various 1,2-disubstituted cyclobutanes.¹⁶


In conclusion, cyclopropyl ketopiperazinyl and imidazolidinyl imides undergo reductive rearrangement to the corresponding bicyclic *trans*- or *cis*-fused cyclobutyl derivatives, respectively, by sequential treatment with DIBAL-H and $\text{BF}_3\cdot\text{OEt}_2/\text{Et}_3\text{SiH}$. The incorporation of an allyl group upon the replacement of Et_3SiH with TMS-allylsilane suggests a more general use for this transformation. The extensive utility of piperazines and imidazolidinones and their derivatives in medicinal chemistry will render these unique analogs of interest in drug discovery.¹⁷

References and notes

- Jonas, W.; Nilsson, J. W.; Thorstensson, F.; Kvarnström, I.; Oprea, T.; Samuelsson, B.; Nilsson, I. *J. Comb. Chem.* **2001**, *3*, 546.
- MDL Information Systems, Inc. Copyright Elsevier MDL.
- For recent examples, see: (a) Thornberry, N. A.; Weber, A. E. *Curr. Top. Med. Chem.* **2007**, *7*, 557; (b) Komoriya, S.; Kobayashi, S.; Osanai, K.; Yoshino, T.; Nagata, T.; Haginoya, N.; Nakamoto, Y.; Mochizuki, A.; Nagahara, T.; Suzuki, M.; Shimada, T.; Watanabe, K.; Isobe, Y.; Furugoori, T. *Bioorg. Med. Chem.* **2006**, *14*, 1309; (c) Doss, G. A.; Miller, R. R.; Zhang, Z.; Teffera, Y.; Nargund, R. P.; Palucki, B.; Park, M. K.; Tang, Y. S.; Evans, D. C.; Baillie, T. A.; Stearns, R. A. *Chem. Res. Toxicol.* **2005**, *18*, 271.
- (a) Ognyanov, V. I.; Balan, C.; Bannon, A. W.; Bo, Y.; Dominguez, C.; Fotsch, C.; Gore, V. K.; Klionsky, L.; Ma, V. V.; Qian, Y.-X.; Tamir, R.; Wang, X.; Xi, N.; Xu, S.; Zhu, D.; Gavva, N. R.; Treanor, J. J. S.; Norman, Mark H. *J. Med. Chem.* **2006**, *49*, 3719; (b) Plobeck, N.; Delorme, D.; Wei, Z.-Y.; Yang, H.; Zhou, F.; Schwarz, P.; Gawell, L.; Gagnon, H.; Pelman, B.; Schmidt, R.; Yue, S. Y.; Walpole, C.; Brown, W.; Zhou, E.; Labarre, M.; Payza, K.; St-Onge, S.; Kamassah, A.; Morin, P.-E.; Projean, D.; Ducharme, J.; Roberts, E. *J. Med. Chem.* **2000**, *43*, 3878; (c) Chu, D. T. W.; Nordeen, C. W.; Hardy, D. J.; Swanson, R. N.; Giardina, W. J.; Pernet, A. G.; Plattner, J. J. *J. Med. Chem.* **1991**, *34*, 168.
- (a) Pedregal, C.; Ezquerro, J.; Escribano, A.; Carreno, M. C.; Ruano, J. L. G. *Tetrahedron Lett.* **1994**, *35*, 2053; (b) Liang, N.; Srinivas, P.; Datta, A. *Tetrahedron Lett.* **2005**, *46*, 7221.
- For related rearrangements of aminocyclopropanes, see: (a) Vergne, F.; Aitken, D. J.; Husson, H.-P. *J. Org. Chem.* **1992**, *57*, 6071; (b) Vergne, F.; Partogyan, K.; Aitken, D. J.; Husson, H.-P. *Tetrahedron* **1996**, *52*, 2421; (c) Notzel, M. W.; Rauch, K.; Labahn, T.; de Meijere, A. *Org. Lett.* **2002**, *4*, 839.
- Hamblett, C. L.; Methot, J. L.; Mampreian, D. M.; Sloman, D. L.; Stanton, M. G.; Kral, A. M.; Fleming, J. C.; Cruz, J. C.; Chenard, M.; Ozerova, N.; Hitz, A. M.; Wang, H.; Deshmukh, S. V.; Nazef, N.; Harsch, A.; Hughes, B.; Dahlberg, W. K.; Szewczak, A. A.; Middleton, R. E.; Mosley, R. T.; Secrist, J. P.; Miller, T. A. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5300.
- As expected, the treatment of diol **7** with $\text{BF}_3\cdot\text{OEt}_2$ and Et_3SiD gave deuterium incorporation:




- Participation by either of the Boc protective groups (**33** and **34** below) would not be long-lived species as both were calculated to be of high energy. In addition, **34** was found to be unstable during QM geometry optimization, converting directly to **12**.



- Khoury, P. R.; Goddard, J. D.; Tam, W. *Tetrahedron* **2004**, *60*, 8103.
- (a) Chaplinski, V.; de Meijere, A. *Angew. Chem., Int. Ed. Engl.* **1996**, *35*, 413; (b) Martin, R. E.; Lack, O. *Tetrahedron Lett.* **2005**, *46*, 8207; (c) Aertgeerts, K.; Brennan, N. K.; Cao, S. X.; Chang, E.; Kiryanov, A. A.; Liu, Y. Arylsulfonylpiperazines and related compounds as hydroxysteroid dehydrogenase inhibitors and their preparation and pharmaceutical compositions. PCT Int. Appl. 2006, WO 2006105127 A2. For alternative methods for the synthesis of cyclopropylpiperazine and protected forms of thereof, see: (d) Chu, D. T. W.; Claiborne, A. K.; Clement, J. J.; Plattner, J. J. *Can. J. Chem.* **1992**, *70*, 1328; (e) Bakshi, R. K.; Nargund, R. P.; Palucki, B. L.; Park, M. K.;

Ye, Z. Preparation of Carbamoylpiperazines as Melanocortin-4 Receptor Agonists. PCT Int. Appl. 2004, WO 2004/024720 A1; (f) Hayakawa, I.; Atarashi, S.; Imamura, M.; Kimura, Y. Preparation of 7-(Azaspiroalkanyl)-quinolonecarboxylates and Analogs as Bactericides. Eur. Pat. Appl. 1990, EP 357047 A1.

12. Attempted reduction of imide **35** with DIBAL-H induced cyclization giving cyclic urea **18** as the only isolable product. Likewise, Cbz-protected amine **36** was bisprotected as Boc imides at elevated temperature with excess Boc anhydride. However, hydrogenolysis of the Cbz protective group led to rapid cyclization giving **37**.



13. For diverse nucleophilic carbon additions to iminium ions, see: Veerman, J. J. N.; Bon, R. S.; Hue, B. T. B.; Girones, D.; Rutjes, F. P. J. T.; van Maarseveen, J. H.; Hiemstra, H. *J. Org. Chem.* **2003**, *68*, 4486.
14. A small degree of hydrolysis to the aldehyde could not be avoided with this substrate. Stability of the aminal following DIBAL-H

reduction is highly substrate dependent, see: Davies, S. G.; Hunter, I. A.; Nicholson, R. L.; Roberts, P. M.; Savory, E. D.; Smith, A. D. *Tetrahedron* **2004**, *60*, 7553.

15. For a related acid-induced rearrangement of an hydroxycyclopropane to a cyclobutanone, see: (a) Truong, M.; Lecornue, F.; Fadel, A. *Tetrahedron: Asymmetry* **2003**, *14*, 1063; (b) Barnier, J. P.; Garnier, B.; Girard, C.; Denis, J. M.; Salaun, J.; Conia, J. M. *Tetrahedron Lett.* **1973**, *20*, 1747; (c) Ollivier, J.; Salaiinq, J. *Tetrahedron Lett.* **1984**, *25*, 1269; (d) Nemota, H.; Ishibashi, H.; Mori, M.; Fujita, S.; Fukumoto, K. *Heterocycles* **1990**, *31*, 1237; (e) Kim, S.-H.; Cho, S. Y.; Cha, J. K. *Tetrahedron Lett.* **2001**, *42*, 8769.
16. For alternative routes to 2-aminocyclobutanols, see: (a) Cannon, J. G.; Crockatt, D. M.; Long, J. P.; Maixner, W. *J. Med. Chem.* **1982**, *25*, 1091; (b) Bisel, P.; Breitling, E.; Frahm, A. W. *Eur. J. Org. Chem.* **1998**, 729.
17. *Representative procedure:* di-*tert*-butyl (1*R*,6*R* and 1*S*,6*S*)-2,5-diazabicyclo[4.2.0]octane-2,5-dicarboxylate (**8**). A stirred solution of di-*tert*-butyl 5,8-dioxo-4,7-diazaspiro[2.5]octane-4,7-dicarboxylate **6** (150 mg, 0.441 mmol) in 2 mL of THF was treated at -78 °C with a 1.0 M solution of DIBAL-H in hexane (1.80 mL, 1.80 mmol) and stirred for 1 h. The reaction mixture was quenched with 2 N Rochelle's salt solution and extracted with DCM. The organic layer was dried (Na₂SO₄), filtered, and concentrated leaving 128 mg (84%) of diol **7** as a 3:1 mixture of diastereomers. Diol **7** (91 mg, 0.26 mmol) was next dissolved in 1.5 mL of DCM and treated at -78 °C with BF₃·OEt₂ (0.15 mL, 1.2 mmol) and Et₃SiH (0.20 mL, 1.25 mmol) and stirred for 2 h. The reaction mixture was quenched with water and extracted with DCM. The organic layer was dried (Na₂SO₄), filtered, and concentrated. The white solid residue was triturated with hexanes to provide 57 mg of **8** (66%). ¹H NMR (600 MHz, DMSO-*d*₆): 4.22 (br s, 2H), 3.55 (br s, 2H), 3.35 (br s, 2H), 2.08 (br s, 4H), 1.45 (s, 18H); ¹³C NMR (150 MHz, DMSO-*d*₆): 155.5, 80.6, 49.8, 41.3, 28.7, 24.7; MS (M+Na⁺) calculated for C₁₆H₂₈N₂O₄Na 335.2, found 335.3.